ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL.

ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL. Clin Infect Dis. 2018 05 17; 66(11):1689-1697.

View in: PubMed

subject areas

Adult
Anti-HIV Agents
CD4 Lymphocyte Count
Drug Therapy, Combination
Female
Heterocyclic Compounds, 3-Ring
HIV Infections
HIV-1
Humans
Lamivudine
Male
Oxazines
Pilot Projects
Piperazines
Pyridones
RNA, Viral
Viral Load

authors with profiles

Beverly Sha